Researchers at the Uniformed Services University in collaboration with University of Washington, have recently uncovered new details about how Nipah and Hendra viruses infect cells and the immune responses that can block them, which could ultimately lead to the development of new tactics to prevent and treat these deadly illnesses.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
People who have certain types of cancers may have an increased risk of having new onset Guillain-Barré syndrome, according to a study published in the March 2, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers found an increased risk in people who had lymphomas and blood cancers, as well as in those who had lung, prostate or breast cancers. The study does not prove that cancer causes Guillain-Barré syndrome. It only shows an association.
The Vasculitis Foundation (VF) is pleased to announce an exciting new initiative: Vasculitis-Building Outcomes, Leading Discoveries (V-BOLD), which combines three of the VF’s most critical programs: Fellowships, Vasculitis Centers, and Research.
The largest clinical review of immune responses to paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, with a focus on infectious diseases, has provided insights into unintended impacts of these commonly used medicines.
A new study using serum from human blood samples suggests neutralizing antibody levels produced by two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against the omicron variant.
People suffering from COVID-19 could have several different SARS-CoV-2 variants hidden away from the immune system in different parts of the body, finds new research published in Nature Communications by an international research team. The study’s authors say that this may make complete clearance of the virus from the body of an infected person, by their own antibodies, or by therapeutic antibody treatments, much more difficult.
Studying mice, researchers at Washington University School of Medicine in St. Louis have discovered that roseolovirus can trigger autoimmunity in a previously unknown way: by disrupting the process by which immune cells learn to avoid targeting their own body's cells and tissues.
Researchers at La Jolla Institute for Immunology (LJI) have discovered new genes in CD4+ "helper" T cell subset that are linked to risk of autoimmune diseases. As they work to shed light on the exact functions of these CD4+ T cell subsets, the researchers have uncovered major differences between donors based on genetics and how the cells may function in men and women.
.png.png&width=400&height=400)
The spectacular structure of the protective armour of superbug C.difficile has been revealed for the first time showing the close-knit yet flexible outer layer – like chain mail.
A Stony Brook University physician-scientist has identified that mucosal-associated invariant T (MAIT) cells exercise several complex roles during healthy and disease states. The published findings may help to serve as a benchmark for future research on MAIT cells as targets for immunotherapies and vaccines.
The Conrad Prebys Foundation has given more than $1.17 million to support La Jolla Institute for Immunology's (LJI) Flow Cytometry Core and more than $415,000 to fuel infectious disease research led by LJI Instructor Julie Burel, Ph.D.
As organisms grow, older cells can undergo a phenomenon called senescence. This process defines a cell state where cells permanently stop dividing but do not die. Senescent cells secrete toxic pro-inflammatory factors contributing to the development of many diseases.
Researchers developed a radio-labeled molecule that allows real-time PET imaging of inflammation and activation of innate immune activity. This would allow physicians to pinpoint areas of inflammation in a variety of clinical settings before symptoms appear.
New research of samples of intestine from people who have died of COVID-19 has shown the impact of the virus on the gut immune system.
A new study suggests that a single bout of exercise does not change the immune response to a coronavirus booster shot in people with rheumatic autoimmune diseases. The article is published ahead of print in the Journal of Applied Physiology.
The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines. A study publishing February 17th in PLOS Pathogens by Anshumali Mittal at the University of Pittsburgh, USA and colleagues describes the structural and functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein and discuss the effects of mutations on the virus spike protein that may allow it to evade antibody responses.
Using powerful tools and techniques developed in the field of structural biology, researchers at the University of Washington and The Scripps Research Institute have discovered new details about the human immunodeficiency virus, HIV.
A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans — including SARS-CoV-2, the cause of COVID-19 — may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.
A one-time infusion of stem cells from bone marrow improves the survival of mice with sepsis, shows a study published today in eLife.
A Kaiser Permanente study published Feb. 14, 2022, in The Lancet Regional Health – Americas found that one month after a third dose, the Pfizer-BioNTech COVID-19 vaccine effectiveness is higher for preventing infection and hospitalization than 2 doses of the vaccine after 1 month.
Asymptomatic COVID infection in generally healthy unvaccinated adults is likely much less common than previously reported, according to a new study published Feb. 14 in Open Forum Infectious Diseases by researchers at the Uniformed Services University of the Health Sciences (USU).
A team headed by Professor Stephanie Pfänder from the Department of Molecular and Medical Virology at Ruhr-Universität Bochum and Dr. Kathrin Sutter from the Institute of Virology at the University Hospital Essen published their findings in the renowned journal PNAS on 22 February 2022 online first.
Antibodies elicited by COVID-19 vaccination become steadily more powerful for at least six months after vaccination, according to a study by researchers at Washington University School of Medicine in St. Louis that involved the Pfizer-BioNTech COVID-19 vaccine.
Participants in the study who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a flu shot or COVID-19 jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization.
A team led by UCLA researchers will receive a multi-million dollar grant to study why some people suffer from a devastating fungal infection called Valley Fever, while others suffer seemingly no impact from the disease.
A paper published this week in the journal Immunity lays the groundwork to better understand and treat Crohn’s disease. The research identified a new role for Interleukin-17A (IL-17A), an immune cell-derived cytokine, in promoting selective epithelial cell development and limiting inflammation during colitis.
Scientists at McMaster University who have developed an inhaled form of COVID vaccine have confirmed it can provide broad, long-lasting protection against the original strain of SARS-CoV-2 and variants of concern. The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection.
People with cancer are often given immunosuppressive treatments that weaken their innate immune defences. This puts them at high risk of severe disease, should they become infected by Coronavirus.
A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine. The study is the first published research examining post–Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will help inform health officials’ approach to vaccine use for outbreak control, the researchers said.
Sequencing more than 170,000 single cells from animal models have provided exceptionally detailed insight into the early immune response to SARS-CoV-2 in the lungs. The findings will help inform future treatment options for the current pandemic and future coronaviruses.
 (002).jpg&width=400&height=400)
Johns Hopkins Medicine researchers report that a prospective study of 14 infants and children demonstrated that convalescent plasma — a blood product collected from patients recovered from infections with the coronavirus (SARS-CoV-2) that causes COVID-19— was safe in high risk children infected with or exposed to the virus.
.jpg&width=400&height=400)
Researchers at McMaster University have found that children who receive years of season-specific flu vaccines develop antibodies that also provide broader protection against new strains, including those capable of causing pandemics.
Asymptomatic viral infections in the first days and weeks of a baby’s life are associated with an increased risk of respiratory infections later in life, research suggests.
Chronic inflammatory bowel disease (IBD) is becoming increasingly widespread. Until now, however, the underlying causes of the inflammation responses were unclear.
Many people have questions about a range of new COVID-19 medications that recently became available to outpatients. Rita Shane, PharmD, vice president of Pharmacy Services and chief pharmacy officer at Cedars-Sinai, is available to comment on key points about these therapies.
In a 38-year-old man who manifested mild symptoms of COVID-19 for 20 days, the novel coronavirus continued to be detected in his organism and to undergo mutations for 232 days.
Questions remain on which vaccine type to get, whether to mix and match types, and how soon after a breakthrough infection to get boosted. To untangle some of these uncertainties, Harvard Medicine News spoke with Jonathan Li, associate professor of medicine at Harvard Medical School and Brigham and Women's Hospital.
Research shows T cells offer protection even against new SARS-CoV-2 variants T cells shield against serious illness, hospitalization, and death from COVID-19 T cell-based vaccines may further boost protection from these critical immune players as the virus continues to shapeshift
George Washington University researchers have developed a blood test that quickly detects if someone has COVID-19 and predicts how severely the immune system will react to the infection, according to a new study coming out today in PLOS One. The findings could one day lead to a powerful tool to help doctors determine the best treatment plan for people with COVID-19.
The make-up of the gut microbiome may be linked to a person’s risk of developing ‘long COVID’ many months after initial infection with SARS-CoV-2, the virus responsible for COVID-19 infection, suggests research published online in the journal Gut.
Blocking a key protein found in Anopheles gambiae mosquitoes—the principal vector for malaria transmission to humans in Africa—could thwart infection with malaria parasites and thus prevent them from transmitting the parasites to humans, according to a study from researchers at the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health.
Here are some of the latest articles we've posted in the Behavioral Science channel.
Many experts now predict that COVID-19, which so far has killed more than 5.5 million people worldwide, will remain endemic as new, infectious variants of SARS-CoV-2 emerge.
New laboratory research from Oregon Health & Science University reveals more than one path toward robust immunity from COVID-19.
The latest research news from the Health Disparities Channel.
Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.
The Global Virus Network (GVN), representing 66 Centers of Excellence and 10 Affiliates in 35 countries comprising foremost experts in every class of virus causing disease in humans, and the Institute of Biomedical Systems and Biotechnologies at Peter the Great St. Petersburg Polytechnic University (SPbPU) announced the addition of the Institute as GVN’s newest Center of Excellence.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
